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Migrene, blodtrykk og renin- angiotensin systemet 
Renin-angiotensin systemet spiller en viktig rolle i reguleringen av blodtrykk i ulike 
deler av kroppen. Systemet finnes også i hjernen hvor det er involvert i en rekke 
funksjoner. Formålet med denne avhandlingen var å se om medikamenter som 
påvirker renin- angiotensin systemet også kunne være effektive som 
migreneforebyggende behandling, og om det var forskjeller mellom migrenepasienter 
og friske kontroller i gener for ulike komponenter i renin- angiotensin systemet. For å 
kaste lys over mekanismene for den gunstige effekten av enkelte blodtrykksmedisiner 
ved migrene ønsket vi også å se på sammenhengen mellom blodtrykk og migrene i 
befolkningen, samt å studere i nærmere detalj eventuelle fysiologiske avvik i 
blodtrykksreguleringen hos migrenepasienter.  
 Hovedfunn i avhandlingen:
1. Atacand (candesartan) er effektivt som forebyggende behandling mot migrene. 
2. Det er ingen sammenheng mellom angiotensin-konverterende enzym (ACE) 
genotype og migrene, og ACE genotype kunne ikke brukes til å forutsi den 
migreneforebyggende effekten av Atacand. 
3. Høyt systolisk blodtrykk og pulstrykk er assosiert med redusert forekomst av 
ikke- migrenøs hodepine og migrene hos voksne i den generelle befolkningen. 
4. Spontan baroreflekssensitivitet og hjerteratevariabilitet var økt hos unge, 
kvinnelige migrenepasienter (uten aura) sammenlignet med friske alders-
matchede kontroller.
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Summary
Background and objectives 
The renin-angiotensin system (RAS) plays an important role in the regulation of blood 
pressure (BP) in different parts of the body. This system is also widely distributed in 
the brain where it is involved in several processes. The aims of this dissertation were 
to explore whether drugs affecting the RAS could be valuable in migraine 
prophylaxis, and whether differences existed between migraine patients and healthy 
controls in genes for different components of the renin- angiotensin system. To shed 
light on the mechanisms of the favourable effect of several antihypertensives in 
migraine, we wished to explore in detail possible physiological differences in the 
regulation of BP in migraine patients.  
Studies
A randomized, double-blind crossover study was performed in 60 patients to 
determine the effect of candesartan compared to placebo in migraine prophylaxis. The  
number of headache days were reduced by 26% in the treatment period with 
candesartan compared to the placebo period. For migraine hours the reduction was 
36%. There was no association between antimigrainous effect and the lowering of the 
BP.
The angiotensin- converting enzyme (ACE) gene insertion/deletion polymorphism 
was determined by polymerase chain reaction (PCR) in 347 patients with migraine 
and 403 healthy controls. No significant difference between patients with migraine 
and controls was found with regard to angiotensin- converting enzyme genotype.  
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Cross-sectional and prospective data from two large epidemiological surveys (HUNT-
1 and HUNT-2) were analyzed to look at the association between BP and headache. 
Groups with high systolic BP and pulse pressure had lower prevalences of 
nonmigrainous headache or migraine in an adult population. 
Baroreflex sensitivity and heart rate variability were measured in 16 women with 
migraine without aura and compared to 14 age-matched controls. Spontaneous 
baroreflex sensitivity and heart rate variability were increased in the migraine 
patients. 
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Migraine, blood pressure and the renin-angiotensin system 
1.   Historical background
Dating back to 7000 BC, skulls have been found bearing man made holes (called 
trepanation) presumably done for medical reasons which may have included the 
treatment of headache in order to release demons and evil spirits from the head (1). 
Even as late as 1660, the famous Dr. William Harvey recommended trepanation to a 
patient with what appears to have been intractable migraine. The Ebers Papyrus (2), 
dating back to about 1200 BC, mentions migraine, neuralgia, and shooting head pains. 
Following the instructions on the papyrus, the Egyptians would firmly bind a clay 
crocodile holding grain in its mouth to the head of the patient. Hippocrates (400 BC) 
may have been the first to describe the clinical symptoms of migraine.  In the 
Hippocratic books he describes a shining light, usually in the right eye, followed by 
violent pain beginning in the temples and eventually reaching the entire head and 
neck area. The term “migraine’ itself is derived from the Greek word hemicrania (1).  
2.   Migraine pathophysiology
Migraine is a common neurological disorder characterized by recurrent attacks of 
disabling headache accompanied by nausea/vomiting, photo- and phonophobia. Some 
of the patients also experience transient focal neurological symptoms prior to the 
headache (migraine with aura). 
The pathophysiology of migraine is still not completely understood but this condition 
is considered to be a neurovascular disorder where there is an activation of the 
socalled “trigeminovascular complex” in genetically disposed subjects (3). The cause 
of this activation is still debated but it may involve sterile meningeal neurogenic 
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inflammation secondary to cortical spreading depression and/or dysfunction of brain-
stem pathways that normally modulate sensory input (4). Important modulation of the 
trigeminovascular nociceptive input comes from the dorsal raphe nucleus, nucleus 
locus ceruleus, nucleus raphe magnus and the periaquaductal grey matter (PAG) (4). 
During a migraine attack calcitonin gene-related peptide (CGRP) and substance P 
(SP) are released from sensory nerve endings (5) and these transmitters are thought to 
sensitize trigeminal neurons to convey nociceptive signals to the brain stem (6). 
3.   Migraine prophylactic medication
Two types of migraine drug therapy exists; acute and prophylactic. Acute medication 
is taken when the attack has started and aims at treating the head pain and other 
symptoms. Prophylactic medication is taken every day and aims at reducing the 
frequency and/or intensity of the attacks. Recent evidence also suggests that this type 
of treatment enhances the patient’s response to acute migraine therapies, and it may 
hopefully also reduce the likelihood of developing chronic daily headache (7).
Migraine prophylactic treatment may be indicated if the patient experiences more than 
2-3 severe migraine attacks per month. Other factors that count in favour of 
prophylactic treatment are long or severe attacks, insufficient effect or troublesome 
adverse effects of acute medication, overuse of acute medication, or if there are co-
morbid conditions for which the preventative drug may have a beneficial effect. Each 
prophylactic drug should be tried for at least 2-3 months at a sufficient dose while 
keeping a headache diary for evaluation of efficacy. Success is generally defined as 
50% reduction in attack frequency, a significant decrease in attack duration or 
improved response to acute medication (7). About one third of migraineurs fulfil the 
criteria for use of prophylactic treatment, according to epidemiological studies, but 
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only 3-13% of patients do actually use this kind of treatment (8). One of the reasons 
for this may be lack of efficacy or the adverse effects associated with this type of 
long-term treatment.  
Substances used for migraine prophylactic treatment include certain antihypertensive 
drugs (propranolol, flunarizine), antiepileptic drugs (valproate, topriamate) and 
antidepressant drugs (amitriptyline). The exact mode of action of these drugs in 
migraine is unknown, and several of them have side-effects that for many patients are 
not compatible with long-term use. 
4.   Blood pressure and the baroreflex system
Blood pressure (BP) is a measure of the force applied to the walls of the arteries as the 
heart pumps blood through the body. The pressure is determined by the force and 
amount of blood pumped, and the size and flexibility of the arteries. BP is continually 
changing depending on activity, temperature, diet, emotional and physical state, 
posture, and medication use. BP is usually represented  by two values. The systolic 
arterial pressure is defined as the peak pressure in the arteries, which occurs at the 
beginning of the cardiac cycle; the diastolic arterial pressure is the lowest pressure 
which is present in the resting phase of the cardiac cycle. BP is also characterized by 
its pulsatile and steady components. The pulsatile component, estimated by pulse 
pressure (PP) (systolic BP minus the diastolic BP), represents BP variation during the 
cardiac cycle and is affected by left ventricular ejection fraction, arterial stiffness, 
early pulse wave reduction, and heart rate. The steady component, estimated by mean 
arterial pressure (MAP), is a function of left ventricular contractility, heart rate, and 
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vascular resistance and elasticity averaged over time. MAP is defined as 1/3 systolic 
blood pressure (SBP) + 2/3 diastolic blood pressure (DBP). 
Short-term regulation of arterial pressure involves arterial baroreceptors (Figure 1) 
exerting a chronotropic effect on the heart and regulating sympathetic outflow. A 
lowering of the BP leads to a reduction in impulses sent from the baroreceptors 
thorough the glossopharyngeal and vagus nerves to the nucleus of the tractus 
solitarius (NTS) in the dorsomedial medulla. This leads to decreased output from the 
vagus nerve to the sinus node, resulting in increased heart rate. A second efferent 
pathway is mediated by central projections from the NTS to presympathetic neurons 
in the rostral ventrolateral medulla (RVLM) resulting in sympathetic inhibition, 
leading to increased vascular resistance (9).  
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Figure 1:  Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 
2008;358:615-24  (PVN = paraventricular nucleus. SON = supraoptic nucleus. RVLM = Rostral 
ventrolateral medulla. NTS = Nucleus tractus solitarius. NA = Nucleus ambiguous. A1 = A1 cell 
group. CVLM = Caudal ventrolateral medulla.)
 In addition there is strong evidence that arterial baroreceptors, through afferents 
terminating in the NTS, may modulate cerebral blood flow through direct connections 
with pontine parasympathetic neurons (10). The baroreflex sensitivity (BRS) is a 
measure of the effectiveness of the baroreflex system. BRS is defined as pulse interval 
variations when the SBP changes, i.e. the slope of linear regression of RR intervals on 
the electrocardiogram versus SBP. Different factors influence BRS in the healthy 
population, including sex, age, BP, heart rate, body mass index, arterial stiffness, 
blood glucose and insulin levels, physical fitness and medication (11).  
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5.   Hypertension associated hypalgesia
Hypertension--associated hypalgesia is a phenomenon that was first reported in 1979. 
Increasing the BP pharmacologically in rats reduced their avoidance reaction 
following a mildly aversive trigeminal nucleus stimulus (12). This effect was not seen 
in rats with denervated baroreceptors. In another study (13) occlusion of rat 
abdominal aorta proximal to the renal arteries resulted in both increased BP and 
antinociception, while occlusion distal to the renal arteries had neither of these effects. 
A neurophysiological investigation even detected attenuation in spinal nociceptive 
transmission in hypertensive rats (14). Later, studies have shown a reduced perception 
of painful stimuli in hypertensive human individuals (15, 16). There is evidence that 
stimulation of the baroreflex arch due to increased BP may inhibit pain transmission 
at both spinal and supraspinal levels, possibly due to an interaction of the centres 
modulating nociception and cardiovascular reflexes in the brainstem (17). Within the 
central nervous system, the baroreflex influences several important sites in pain 
modulation, and it has been demonstrated that a substantial number of PAG neurons 
and neurons in the nucleus raphe magnus are excited by pharmacologically induced 
changes in BP (12, 18). In addition, stimulation of the NTS, which is the terminal site 
of baroreceptor afferent fibers, induces antinociception (15). The nucleus reticularis 
gigantocellularis in the medulla oblongata may also be an important site in BP-related 
nociceptive modulation, and angiotensin III, a peptide derived from angiotensin II 
(Ang II), is thought to act as a transmitter here (19). 
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6.   The relationship between blood pressure and migraine
For many years it was assumed that hypertension might be a cause of headache. 
Studies supporting this connection were published and the pulsating characteristic of 
some headaches and the introduction of ȕ-blockers in migraine prophylactic treatment 
may further have supported this view (20, 21). However, this observation may be an 
example of admission rate bias (Berkson’s bias) as hypertension and headache are 
common medical disorders and consulting the doctor for one of the disorders may 
give a higher likelihood of detecting the other condition. Later, epidemiological 
studies showing no relationship between headache and high BP were published (22, 
23), and in the International Classification of Headache Disorders II it is stated that 
mildly or moderately elevated BP is not a cause of headache (24). This was confirmed 
in 2002 by prospective data from a large unselected population in Norway (The Nord-
Trøndelag Health Study – HUNT) on 22 685 adults, and this study even indicated that 
high systolic and diastolic pressures might be associated with reduced risk of non-
migrainous headache 11 years later. For migrainous headache no clear association 
was found (25). A prospectively planned cohort study from Brazil (26) with 1763 
hypertensive patients demonstrated a negative association between SBP and headache 
prevalence, a positive association between DBP and headache and a negative 
association between pulse pressure (PP) and headache. Another group has also 
demonstrated that in 1174 adults those with normal BP complained of migraine more 
frequently than participants with high BP (27). In a French population of 1373 
subjects, migraine patients had lower SBP and lower PP than controls (28). In 
accordance with this a population-based study from Iceland with 21 537 subjects 
found that individuals with migraine had lower PP, lower SBP and higher DBP than 
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controls (29). This inverse relation is not restricted to headache (30) but seems to be 
as valid for pain in other parts of the body.
However, in favour of the hypothesis that hypertension causes migraine, one may cite 
the large meta-analysis of 94 randomized placebo-controlled trials of different 
antihypertensive drugs in which headache was registered as an adverse event, 
demonstrating a preventive effect on headache (31). It is also a fact that many, but not 
all, antihypertensive drugs have a well established place in migraine prophylactic 
therapy. Hence, the relationship between BP and headache is not well understood and 
deserves further scrutiny. 
7.   The cerebral renin angiotensin system
Since it was discovered in 1898, the renin-angiotensin system (RAS) was thought to 
be a hormonal system by which the kidney influences systemic cardiovascular 
regulation. In the classic model, renin, excreted by the kidneys, cleaves 
angiotensinogen from the liver into angiotensin I. This decapeptide is then cleaved 
into Ang II by angiotensin-converting enzyme (ACE) which is abundant in the 
pulmonary endothelium. Ang II has two receptors, AT1 and AT2 which are expressed 
in many cardiovascular and other tissues (32). 
Later it was discovered that injecting Ang II into the general circulation also elicited 
effects in the central nervous system (33). Ang II does not cross the blood brain 
barrier, and AT1 and AT2 receptors responding to circulating Ang II were discovered 
in the circumventricular organs lacking a normal blood brain barrier (34), and later in 
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cerebrovascular endothelial cells. In addition several local tissue Ang II systems have 
been discovered in numerous organs, including the brain (35). These systems appear 
to be regulated independently of peripheral Ang II (36). In the brain all components of 
the classical RAS , such as angiotensinogen, renin, ACE, Ang II and the AT1 and 
AT2 receptors, are present.  
Ang II is involved in many important processes in the brain. It influences 
cerebrovascular flow, the production of nitric oxide (NO) and the release of hormones 
(vasopressin and oxytocin). It increases sympathetic nervous activity and acts as a 
potent vasoconstrictor. Blockade of the AT1 receptor has also been shown to reverse 
cerebrovascular inflammation and can possibly decrease vulnerability to cerebral 
ischemia (37).   
8.   The angiotensin system in migraine
8.1    Clinical evidence
In 1981, after the ACE inhibitors (ACE-Is) had become available as 
antihypertensives, it was known that circulating opioids (particularly enkephalins) 
were metabolized by enkephalinase and ACE (38). This provided the motivation for 
the group of Sicuteri  to study the effect of ACE-Is on 35 patients suffering from 
idiopathic headaches (ophthalmic migraine [4], common migraine [16] and mixed 
headache [15]). Essential hypertension was present in 11 of the patients. All patients 
were treated with an ACE-I (captopril) for periods lasting from 1 to 6 months (39). An 
initial dose of 25 mg was increased to 100 mg within a week. The subjects had 
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previously used different migraine prophylactic agents with variable effect. Of the 35 
patients, 23 reported a 50% or more headache reduction on captopril. 
In 1995, a small open study by Bender (40) explored the use of the ACE-Is enalapril 
(most) or lisinopril (some) in 17 patients with migraine. The medication was given 
once daily in doses from 10 to 25 mg for a period of 3 months to 3 years. 10 patients 
reported a marked effect on their headache, in six the effect was moderate, and in one 
there was only a slight effect. 
In 2001, a double-blind, randomized, placebo-controlled crossover study of an ACE-I 
(lisinopril) (41) was published by doctors from the department of Neurology in 
Trondheim, including 60 patients who suffered from migraine according to the 
diagnostic criteria of the International Headache Society. In the per-protocol analysis 
of 47 patients hours with headache, days with headache, days with migraine, and 
headache severity index were significantly reduced (by 20, 17, 21 and 20%, 
respectively) in the lisinopril period compared to the placebo period. The number of 
days with migraine was reduced by at least 50% for active treatment compared to 
placebo in 14 participants, and for active treatment compared to the run-in period in 
17 patients. The intention-to-treat analysis supported the difference in favour of 
lisinopril for the primary endpoints. With respect to the side-effects, there was 
markedly more cough, dizziness and tendency to faint in the active period than in the 
placebo period. 
In 2006, an open-label study (42) examined the effect of the Angiotensin II receptor 
blocker (ARB), olmesartan, in 24 subjects aged 27 to 76 with either hypertension or 
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prehypertension and migraine. They were treated with 10 to 40 mg of olmesartan for 
at least 3 months, and endpoint data were collected by asking the patients about the 
frequency and severity of their headache. Patients reported an 82.5% average 
reduction in the frequency of migraine attacks and a 45% average reduction in the 
severity of migraine attacks. The only side-effects registered were dizziness and 
presyncope. There were no serious adverse events and no patients had to be 
withdrawn from the study due to intolerance to the drug. 
8.2   Clinical indirect evidence
In 2002 a meta-analysis of 27 randomized, placebo-controlled trials on ARBs in 
hypertension looked at headache as an adverse event (43). In the 12 110 patients the 
overall risk of headache was about 30% lower in the group receiving ARBs compared 
with those taking placebo. 
In 2003 1537 elderly hospitalized patients diagnosed with hypertension were asked 
about headache after they had received nitrates during the hospital stay (44). Patients 
using ACE-Is had a 56% reduced risk of headache compared to those using other 
types of antihypertensives, even though the BP reduction was the same in both 
groups.
In 2004 a large pharmacological database provided information about the 
consumption of specific migraine-abortive drugs (ergotamine or a triptan) before and 
after patients started receiving treatment with an ACE-I, an ARB or a diuretic (45). 
The patients using ACE-Is or ARBs showed a significant reduction in the 
consumption of migraine-abortive drugs compared to those using diuretics. If the 
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antihypertensive treatment was stopped, the use of migraine-abortive drugs increased 
again in those who had received ACE-Is or ARBs, but not in those who had used 
diuretics.
8.3   Genetic evidence
Migraine is a multifactorial disorder with both environmental and genetical 
components. It is today generally accepted that both migraine with and without aura 
have a considerable genetic component, but whether they share a common genetic 
cause is still unknown (46). 
In 2000, an Italian group examined the frequency of polymorphisms of the ACE gene 
in 302 patients with migraine without aura compared to 201 healthy controls (47). The 
human ACE gene locus occurs with either an insertion (I) or a deletion (D) allele, 
resulting in three genotypes: II, ID and DD. In the migraine patients the ACE-DD 
polymorphism occurred more often (48%) than in the control population (37%). The 
frequency of migraine attacks was also greater (2.1 attacks per week on average) in 
patients with the DD genotype than in those with the ID genotype (1.5 attacks on 
average per week). No difference was found in the duration of migraine attacks, and 
plasma ACE was increased in patients with the ACE-DD genotype. 
In 2005, a Japanese study (48) with 54 patients suffering from migraine with aura, 
122 patients with migraine without aura, 78 with tension-type headache and 248 
healthy controls showed the DD genotype to be more prevalent among the migraine 
with aura patients. 
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In 2005, an Australian group found evidence that the methylenetetrahydrofolate 
reductase (MTHFR) TT genotype and the ACE (ID/DD) genotypes act in 
combination to increase susceptibility to migraine (OR 2.18) (49). The C677T 
mutation in the MTHFR gene has previously been shown to be a risk factor for 
migraine (50). Two hundred and seventy migraine patients with and without aura 
were compared to 270 healthy controls and no difference in genotype or allele 
frequencies was found. 
In 2005, a Taiwanese study (51) with 240 migraine patients and 200 healthy controls 
found no difference in genotype or allele frequencies between the groups. 
Stratification by gender, however, showed more of the DD genotype in male 
migraineurs. No difference in headache frequency or duration was found. 
In 2007, a Turkish group investigated ACE genotypes and matrix metalloproteinase -3 
(MMP-3) genotypes in 59 migraine patients with aura, 109 without aura, 10 with 
basilar migraine and two with complicated migraine (52). The control croup consisted 
of 210 healthy individuals. ACE is a bivalent dipeptidyl carboxyl metalloproteinase 
and given that it shares ancestry with MMP-3 they were both examined. 
The frequencies of 5A5A genotypes of the MMP-3 and D-allele of ACE were 
elevated while the 6A allele of MMP-3 and II genotype of ACE were decreased in 
migraine patients compared to controls. 
8.4   Physiological and biochemical evidence
In animal studies conflicting results have been found concerning the role of the RAS 
in nociception. In different studies ARBs and ACE-Is have been found to both 
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promote and prevent pain transmission. Ang II injected directly into the cerebral 
ventricles has been shown to both antagonize morphine-induced antinociception (53) 
and to produce an analgesic effect that can be blocked by naloxone (54). Similarly, 
ARBs and ACE-Is may both block and promote cerebral antinociception (55, 56).  In 
one study (57) injecting Ang II into the periaquaductal grey area of rats resulted in 
antinociceptive effects that could be reversed by an ARB administered simultaneously 
into the same area. However, ARBs and ACE-Is administered daily by mouth have 
produced antinociceptive effects, whereas no such effect was obtained with a single 
dose (58). Perhaps this may indicate that long-term administration results in an 
improved penetration of the blood brain barrier. 
SP and CGRP are both vasoactive neuropeptides thought to be involved in the 
neurogenic inflammation that may be present during migraine attacks. A Japanese 
study (59) examined the levels of these transmitters in addition to ACE which is 
known to degrade SP. Forty-one patients suffering from migraine with aura, 54 
without aura and 52 healthy controls were included and only interictal measurements 
were performed. Levels of CGRP and SP were higher in both migraine with and 
without aura patients while the ACE level was higher in the migraine with aura group. 
In migraine with aura patients there was a positive correlation between SP level and 
ACE activity. This is the opposite tendency of what would be expected if increased 
ACE activity leads to increased degradation of SP, and the results of this study may 
indicate that ACE is involved in migraine pathophysiology. 
A hypothesis that mast cells activating the RAS may contribute to migraine has also  
been proposed (60). Mast cells in the meninges are located perivascularly where 
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several triggers may lead to degranulation (61). This may result in meningeal 
irritation, vascular dilatation and stimulation of nociceptive nerve endings of the 
trigeminal nerve (60). Ang II is known to enhance mast cell degranulation (62) and 
there is also evidence that mast cells are capable of releasing renin and increase local 
production of Ang II (63). Stress is a main trigger for migraine attacks, and one 
explanation for this may be that stress can induce mast cell degranulation 
intracranially by release of corticotrophin-releasing hormone (CRH) (64).  
In addition to mast cell degranualation, there are several ways in which Ang II may 
contribute to neurogenic inflammation. Nuclear factor-kappaB (NF-kappaB) is 
cytoplasmic transcription factors that are associated with increased expression of 
inducible nitric oxide synthase (iNOS), a mediator of the inflammatory response 
associated with migraine attacks (65, 66). These transcription factors are activated by 
Ang II and prevented by ARBs and ACE-Is (67, 68). Ang II has also been shown to 
increase oxidative stress in the central nervous system by inducing production of 
superoxide (69). Oxidative stress has been associated with migraine, and a migraine 
prophylactic agent, flunarizine, has been found effective in limiting the oxidative 
reactions occurring in migraine sufferers (70). Endothelin-1, a potent vasodilator 
possibly linked to migraine pathophysiology, is also stimulated by Ang II (71). 
CGRP, which is released from activated trigeminal neurons during a migraine attack 
is perhaps one of the most important mediators in migraine pathophysiology known 
today. Two selective CGRP antagonists have also been shown effective in the 
treatment of migraine attacks (72). Ang II can stimulate the release of CGRP (73) and 
can therefore possibly be involved in maintenance of the migraine attack. 
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The central sensitization theory of migraine proposes that altered processing of 
sensory input in the brainstem, could account for many of the features of migraine. 
The N-methyl-D-aspartate (NMDA) receptor is important for the central sensitization 
process and there is evidence that ARBs, by blocking the AT1 receptor, may increase 
the stimulation of the AT2 receptor, resulting in AT2 receptor-mediated inhibition of 
NMDA signalling in neuronal cells (74). Theoretically this might reduce induction of 
central sensitization in migraine (75). 
9.   Premises for and methods of the studies in this thesis
9.1   Methodology of the candesartan study
A randomized, double-blind placebo controlled study is the gold standard to measure 
the effect of a drug. In the candesartan study, a cross-over design was chosen to 
obtain sufficient statistical power in a relatively small study which could be feasible 
in a single centre. Sixty migraine patients aged 18 to 65 years with 2 to 6 migraine 
attacks per month were recruited mainly from newspaper advertisements. After a 4-
week single-blind placebo run-in period to verify the frequency of attacks, patients 
were randomized to either 12 weeks of candesartan 16 mg daily or placebo. The 
patients then entered a 4-week wash-out period before they crossed over so that those 
having received active medication in the first treatment period received placebo in the 
second, and vice versa. 
9.2   Headache biobank of the Norwegian National Headache Centre
The main purpose of the Norwegian National Headache Centre is to generate and 
spread knowledge of the different headache disorders. In order to do so most 
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effectively and to provide material for this thesis, a headache biobank was established 
in 2004. The reason for including patient material in a biobank is to ensure that the 
collection, management and destruction of the material is handled in an ethical way. 
In the headache biobank all patients with one or more headache diagnoses verified by 
a neurologist are eligible for inclusion. From each participant 10 ml of blood is 
collected and stored in 5 different containters frozen at -80 degrees Celsius. In 
addition a registration form containing information about the features of the patient’s 
headache is filled out. Material from this biobank was used in the ACE polymorphism 
study. Genetic analyses were performed in UK (AstraZeneca R&D Genetics) and at 
the lab of Neurobiology, St.Olavs Hospital. 
9.3   The North-Trøndelag Health Study (HUNT)
Epidemiology is the study of how often diseases occur in different groups of people 
and why. The advantage of using data from the HUNT study to investigate the 
relationship between BP and headache was the large and unselected population, the 
use of validated diagnoses and the availability of both cross-sectional and prospective 
data.
The North-Trøndelag Health Study (Norwegian acronym is HUNT), one of the 
world’s largest epidemiological surveys, was performed in the Norwegian county of 
North-Trøndelag, which has a total population of 126 000, 92 566 of which are above 
the age of 20.
The first study, HUNT-1, was conducted between 1984 and 1986, mainly focusing on 
BP and diabetes. Inhabitants aged 20 and older were invited to participate, and of 85 
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100 eligible subjects, 77 310 (91%) answered the questionnaire, attended a medical 
examination and had their BP measured. 
HUNT-2, a more comprehensive follow-up of HUNT-1, was performed between 1995 
and 1997. 64 560 (70%) of 92 566 invited subjects participated and 51 353 (56%) 
who attended a medical examination had their BP measured and responded to a 
headache questionnaire. Diagnoses obtained were validated (76). 
9.4   Measurements of baroreflex sensitivity (BRS) and heart rate variability (HRV)
The measurements were performed in the department of Neurology and Clinical 
Neurophysiology, St.Olavs Hospital.
Heart rate variability (HRV) and BRS are used to assess the activity in the autonomic 
nervous system. HRV is a measure of the tonic autonomic heart rate control, whereas 
BRS measures the dynamic autonomic heart rate control (77). The RR-interval in the 
ECG is the time measured between two heartbeats. HRV refers to the beat-to-beat 
alterations in heart rate. Prior to analysis of a time period, ectopic beats will have to 
be removed and the rate interpolated. A statistical mapping of normal-to-normal beat 
intervals (NN-intervals) can be performed with different techniques. Spectral analysis 
with Fourier transformation (frequency domain technique) enables calculation of total 
power which is the variability of the NN-intervals in the frequency band 0- 0.40 Hz. 
In addition, high frequency ( HF 0.15- 0.40  Hz), low frequency (LF 0.04- 0.15 Hz) 
and very low frequency (VLF 0- 0.04 Hz) bands can be calculated. These different 
parts of the spectra give information about the activity of the autonomic nervous 
system, as only the parasympathetic nervous system is able to generate the rapid 
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changes of heart rate in the HF band. In the LF band both the parasympathetic and 
sympathetic nervous systems are able to alter the heart frequency (77). The VLF is 
influenced by many other factors (chemoreceptors etc). Another way of calculating 
HRV is by use of the time-domain technique. This is a mapping of the NN-intervals 
using the standard deviation of successive NN-intervals (SDNN) or the root mean 
square of successive NN-intervals (RMSSD).  
BRS is defined as change in RR-interval as a result of change in BP and is measured 
in ms/mmHg. If the SBP increases with 1 mmHg and the RR-interval is increased 
with 10 ms, the BRS is 10 ms/mmHg. To calculate BRS, series with at least 3 
successive heart beats in which the SBP either increases or decreases are detected. 
Then the correlation coefficient for the regression line between the systolic pressures 
and the RR-intervals is calculated, and the BRS is the average of several such 
correlation coefficients (78). 
10.   Discussion
For headache research, it always helps having a professor with migraine in your 
department. Most drugs used for migraine prevention have been discovered by 
serendipity or educated guesses, and professor Harald Schrader made the connection 
when he used lisinopril for treating his hypertension and discovered that this migraine 
disappeared. He then tried it out on a few patients with excellent response. As 
lisinopril proved valuable in migraine prevention (41), the question was whether 
direct blockade of the receptor of the major RAS effector (Ang II) could provide 
better effect. This elicited my interest in the RAS, both as a main regulatory system 
for BP, but most importantly as an independent modulatory system for processes in 
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the brain. This lead us to explore the connection between the RAS, migraine and BP 
with clinical, genetic, epidemiological and neurophysiological investigations. 
10.1   Candesartan in migraine prophylaxis
Alleviating the burden of migraine allows sufferers to live normal lives, unhindered 
by the disability and considerable discomfort associated with the condition. It may 
also offer important socioeconomic benefits (79) by reducing headache-related 
absenteeism from the workplace. In migraine prevention it is desirable that medicines 
are efficient and well tolerated, but unfortunately current prophylactic drugs do not 
meet these demands. 
Using the ARB candesartan we demonstrated for the first time efficacy of this drug in 
migraine prophylaxis. Direct comparison of results between the candesartan study and 
studies with other migraine prophylactics is difficult to perform due to differences in 
design and endpoints. Our study was also conducted with a crossover design 
providing placebo- subtracted results, which gives a more conservative estimate of the 
real effect than most other studies that have a parallel group design, reporting 
differences from baseline. The efficacy of candesartan was, however, of the same 
order of magnitude as reported in previous studies (80-84). The number of adverse 
events in the treatment period was similar to that in the placebo period, which is in 
accordance with the good tolerability profile shown in other studies on candesartan 
used as an antihypertensive agent (85). In addition to its good efficacy and tolerability 
in our study it has the advantage of being administered just once daily. 
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The mechanism of effect is not known, but as mentioned in the Background section, 
there are many ways in which the cerebral RAS may act in modulating pain. A direct 
blockade of AT1 receptors in the brain is possible. There may also be a direct effect 
on the peripheral BP, but this seems less likely since there was no association between 
response to the drug and degree of BP reduction. In light of the epidemiological 
findings that high BP is associated with less headache, it is an interesting hypothesis 
that the drug, by lowering the BP, triggers reflex mechanisms to counteract the 
hypotensive stimulus, and that these mechanisms in some unknown way can improve 
the headache. 
In order to evaluate the long term effect of candesartan in migraine prophylaxis a 
questionnaire was sent one year after completion of the study to the 18 responders  
and they were also asked to keep a headache diary for one month (Not published 
data). 13 responded and no reminder was sent. Of these 10 were still using 
candesartan and 9 of these completed the one-month headache diary. A total of 29 
headache days were reported during follow-up, and in the one-month placebo run-in 
period the same patients reported 62 headache days. This may give an indication that 
candesartan may be effective in preventing migraine for at least a period of 1-2 years.
10.2   ACE I/D polymorphism in migraine
After having found an effect of drugs influencing the RAS it was natural to ask 
whether migraine might be due to some derangement in this system, and possibly the 
genes involved in its various components. The ACE gene consists of either an 
insertion (I) allele or a deletion (D) allele forming three possible genotypes: II, ID and 
DD. Several studies have looked at the association between the ACE gene and 
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migraine (47-49, 51, 52), but the results are not consistent. Some association between 
these genes and migraine have been found only in subgroups based on diagnostic 
subtype and sex. Our study is the largest performed with more than 700 patients and 
controls, but no association was found in a Norwegian population. For the subgroup 
“migraine without aura”, one study had a larger patient sample (47). Even though our 
study has > 80% power to detect an association of the same magnitude, a relationship 
between the DD-polymorphism and migraine cannot be completely ruled out. 
However, the fact that other studies (48, 49, 51) also were negative for this subgroup, 
makes such an association less likely. The studies were done in different ethnic 
populations (Norwegian, Italian, Japanese, Taiwanese, Australian) that may display 
different genotypic patterns. 
We also wanted to investigate whether the ACE I/D polymorphism might predict 
clinical response to either lisinopril or candesartan in migraine prophylaxis. In order 
to be clinically relevant, we decided that at least 75-100% of the responders would 
have to have a specific genotype. If this turned out to be the case, genotyping could be 
an alternative to trying out the drugs for two to three months. However, we found no 
clinically significant predictive value of ACE genotype.  
10.3   Blood pressure and headache
Like candesartan, several of the drugs used for migraine prophylaxis have a BP-
lowering effect (31). It was therefore of interest to investigate the relationship 
between headache and BP, and we used data from one of the world’s largest 
epidemiological surveys, the HUNT study. High systolic and high pulse pressure 
turned out to be associated with a decreased prevalence of non-migrainous headache 
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and migraine, and the use of antihypertensive medication tended to weaken this 
relationship.
Against this background it may seem to be a paradox that many antihypertensive 
medicines, which lower both the BP and PP, are effective in migraine prophylaxis. 
One possible explanation is that hypertension may mediate antinociception in general 
whereas antihypertensive drugs may influence migraine specific mechanisms (e.g. 
acting directly on neuronal activity in the CNS). A lower degree of central 
sensitization has also been demonstrated in healthy subjects in response to pain in 
those with elevated resting BP level, indicating that high BP has a protective effect 
against central sensitization (86). Another possibility is that migraine symptoms are 
reduced through mechanisms indirectly related to the effects on BP. One such indirect 
mechanism may be change in BRS.
Several interesting observations may support the results in this thesis. BP can be 
divided into different components and it is well established that for the same level of 
MAP, different patterns of PP may be observed (87, 88). PP showed the most 
consistent inverse association with headache prevalence, and the fact that the pulsatile 
component is more prominent (increased PP) after the age of 55 (87) may help 
explain why headache prevalence decreases after this age. Another interesting 
observation in support of our results is that PP is significantly higher (89) and the 
BRS greatly reduced (> 40%) in the second and third trimester of normotensive 
pregnant women (90). This may contribute to the fact that the majority of pregnant 
migraine sufferers will note significant improvement in their headaches during the 
second and third trimesters.
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10.4   The baroreflex system and migraine
To evaluate the role of the baroreflex in migraine under normal conditions, we 
measured BRS and HRV in 16 female migraine without aura patients and 14 age-
matched healthy female controls. Even in this small material we found an increased 
spontaneous BRS as well as increased HRV in the migraineurs. Increased BRS is 
associated with lower systolic or pulse pressure (91, 92), which is exactly what was 
found in the subjects with headache in the HUNT-study. This indicates that increased 
BRS may be the reason why patients with migraine (and possibly other painful 
conditions) in general have a lower SBP and PP than those without pain. The high 
BRS may be another manifestation of the generalized increased sensitivity (e.g. 
photo- and phonophobia) seen in migraine patients.
11.   Hypothesis
11.1 Conclusion
Based on the present and previous studies it is tempting to present a hypothesis about 
the relation between migraine, BP and the RAS. This hypothesis can be summarized 
in a few statements: 
1) Migraineurs have a generalized increased sensitivity to stimuli, both light, 
sound, odours, touch and bodily movements. This is particularly exacerbated 
during attacks, but it is also to some degree present outside attacks. 
2) Increased BRS may be another manifestation of increased generalized 
sensitivity.
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3) According to the phenomenon of hypertension-associated analgesia (17), high 
BRS and low BP is associated with more pain, which is in concordance with 
the results found in our studies. 
4) In light of known functional links between key areas in the midbrain and 
brainstem contributing to both pain modulation and autonomic control, it is 
not unlikely that 1),  2) and 3) describe interrelated components in a complex 
feedback system, making it hard to determine that one is the cause of another. 
5) The cerebral RAS may be important for the system described in 4). In addition 
to being one of the main regulatory systems for maintaining BP, it influences 
several factors that are central in migraine pathophysiology like 
cerebrovascular flow, cerebral inflammation processes, the secretion of 
neuropeptides and production of NO. AT1 and AT2 receptors have also been 
found in brainstem areas involved in pain modulation and autonomic 
functions. In incompletely known ways the cerebral RAS therefore may 
mediate the relation between BP and pain sensitivity. 
6) ARBs may have a beneficial effect in migraine because they 
a. Act on cerebral Ang II receptors (AT1 and/or AT2) thereby 
influencing pain modulation in the CNS. 
b. Induce hypotension resulting in baroreceptor stimulation which can 
influence pain perception. 
7) Neither the migraine itself nor the effect of the ARBs is related to differences 
between migraineurs and non-migraineurs in ACE genotype.
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11.2   Weaknesses of the hypothesis
It is a weakness that only two placebo-controlled, randomized studies on drugs 
influencing the RAS have been conducted, one for an ARB and one for an ACE-I. 
More studies are needed to confirm the effect of these drug classes in migraine 
prophylaxis.
An important problem for part of the hypothesis is that some antihypertensives do not 
seem to work in migraine (e.g. diuretics, betablockers with partial agonist activity). If 
6b of our hypothesis is correct, one would believe that all antihypertensives should be 
effective to some degree. 
Also, it is a problem that, although both baroreflex modulation and hypertension are 
known to have an antinociceptive effect (93, 94), the effect of antihypertensive drugs 
on BRS is not clear. Both increase and decrease in BRS have been reported (95-97). 
In addition, we found HRV to be increased in migraine patients, but other papers 
report conflicting results (both decreased and enhanced HRV) (98-101).
As to the point 7 in the hypothesis, one may object that although we did not find any 
difference between migraineurs and controls with regard to ACE genes there are 
many other components of the RAS that may be different in migraine patients. This 
can be clarified through other genetic studies (e.g AT1 receptor genes etc.) 
12.   Future prospects
Further studies on the mechanisms underlying the relation between migraine, BP and 
the RAS are warranted. The effect of candesartan should be confirmed and 
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preferentially be compared to one of the first-line migraine prophylactic agents (e.g 
betablocker). In addition, the influence of the brain RAS in migraine should be 
investigated further. The main effect of Ang II on BP is mediated by blockade of the 
AT1 receptor, but pharmacological manipulation of other parts of the RAS like the 
AT2 receptors, renin or the active metabolites of Ang II (angiotensin 1-7, angiotensin 
III and angiotensin IV) could give further insight into its effect on migraine. Further 
exploration of the genetic components of the RAS like AT1 receptor genes, may also 
provide valuable information. Measuring BRS and HRV before and after treatment 
with an ARB could make clear whether these drugs exert their effect through the 
baroreflex system. Use of ARBs in other headache disorders or other chronic pain 
conditions could further provide insight into how much of the effect is migraine-
specific.
39
References
[1] Olesen J GP, Ramadan NM, Tfelt-Hansen P, Welch KMA. The Headaches. 3 
ed. Philadelphia: Lippincott Williams & Wilkins, 2006. 
[2] Hanington E, Harper MA. The role of tyramine in the aetiology of migraine, 
and related studies on the cerebral and extracerebral circulations. Headache: The 
Journal of Head and Face Pain. 1968;8:84-97. 
[3] Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and 
treatment. N Engl J Med. 2002;346:257-70. 
[4] Alstadhaug KB, Salvesen R. [Migraine--mechanisms and consequences for 
treatment]. Tidsskr Nor Laegeforen. 2007;127:3064-8. 
[5] Goadsby PJ. Recent advances in understanding migraine mechanisms, 
molecules and therapeutics. Trends Mol Med. 2007;13:39-44. 
[6] Giniatullin R, Nistri A, Fabbretti E. Molecular Mechanisms of Sensitization of 
Pain-transducing P2X(3) Receptors by the Migraine Mediators CGRP and NGF. Mol 
Neurobiol. 2008;37:83-90. 
[7] Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007;7:383-
93.
[8] Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. 
Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 
2007;68:343-9.
[9] Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J 
Med. 2008;358:615-24. 
[10] Agassandian K, Fazan VP, Margaryan N, Dragon DN, Riley J, Talman WT. A 
novel central pathway links arterial baroreceptors and pontine parasympathetic 
neurons in cerebrovascular control. Cell Mol Neurobiol. 2003;23:463-78. 
[11] Skrapari I, Tentolouris N, Katsilambros N. Baroreflex function: determinants 
in healthy subjects and disturbances in diabetes, obesity and metabolic syndrome. 
Curr Diabetes Rev. 2006;2:329-38. 
[12] Dworkin BR, Filewich RJ, Miller NE, Craigmyle N, Pickering TG. 
Baroreceptor activation reduces reactivity to noxious stimulation: implications for 
hypertension. Science. 1979;205:1299-301. 
[13] Thurston CL, Randich A. Acute increases in arterial blood pressure produced 
by occlusion of the abdominal aorta induces antinociception: peripheral and central 
substrates. Brain Res. 1990;519:12-22. 
[14] Randich A, Robertson JD. Spinal nociceptive transmission in the 
spontaneously hypertensive and Wistar-Kyoto normotensive rat. Pain. 1994;58:169-
83.
[15] Ghione S. Hypertension-associated hypalgesia. Evidence in experimental 
animals and humans, pathophysiological mechanisms, and potential clinical 
consequences. Hypertension. 1996;28:494-504. 
[16] Zamir N, Shuber E. Altered pain perception in hypertensive humans. Brain 
Res. 1980;201:471-4. 
[17] Guasti L, Zanotta D, Mainardi LT, Petrozzino MR, Grimoldi P, Garganico D, 
et al. Hypertension-related hypoalgesia, autonomic function and spontaneous 
baroreflex sensitivity. Auton Neurosci. 2002;99:127-33. 
[18] Murphy AZ, Ennis M, Rizvi TA, Behbehani MM, Shipley MT. Fos expression 
induced by changes in arterial pressure is localized in distinct, longitudinally 
organized columns of neurons in the rat midbrain periaqueductal gray. J Comp 
Neurol. 1995;360:286-300. 
40
[19] Yien HW, Chan JY, Tsai HF, Lee TY, Chan SH. Participation of nucleus 
reticularis gigantocellularis in the antinociceptive effect of angiotensin III in the rat. 
Neurosci Lett. 1993;159:9-12. 
[20] Walker CH. Migraine and its relationship to hypertension. Br Med J. 
1959;2:1430-3.
[21] Badran RH, Weir RJ, McGuiness JB. Hypertension and headache. Scott Med 
J. 1970;15:48-51. 
[22] Buring JE, Hebert P, Romero J, Kittross A, Cook N, Manson J, et al. Migraine 
and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol. 
1995;52:129-34.
[23] Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a 
general population. Neurology. 1992;42:1225-31. 
[24] The International Classification of Headache Disorders. 2nd Edition. 
Cephalalgia. 2004;24:1-160. 
[25] Hagen K, Stovner LJ, Vatten L, Holmen J, Zwart JA, Bovim G. Blood 
pressure and risk of headache: a prospective study of 22 685 adults in Norway. J 
Neurol Neurosurg Psychiatry. 2002;72:463-6. 
[26] Fuchs FD, Gus M, Moreira LB, Moreira WD, Goncalves SC, Nunes G. 
Headache is not more frequent among patients with moderate to severe hypertension. 
J Hum Hypertens. 2003;17:787-90. 
[27] Wiehe M, Fuchs SC, Moreira LB, Moraes RS, Fuchs FD. Migraine is more 
frequent in individuals with optimal and normal blood pressure: a population-based 
study. J Hypertens. 2002;20:1303-6. 
[28] Tzourio C, Gagniere B, El Amrani M, Alperovitch A, Bousser MG. 
Relationship between migraine, blood pressure and carotid thickness. A population-
based study in the elderly. Cephalalgia. 2003;23:914-20. 
[29] Gudmundsson LS, Thorgeirsson G, Sigfusson N, Sigvaldason H, Johannsson 
M. Migraine patients have lower systolic but higher diastolic blood pressure 
compared with controls in a population-based study of 21,537 subjects. The 
Reykjavik Study. Cephalalgia. 2006;26:436-44. 
[30] Hagen K, Zwart JA, Holmen J, Svebak S, Bovim G, Stovner LJ. Does 
hypertension protect against chronic musculoskeletal complaints? The Nord-
Trøndelag Health Study. Arch Intern Med. 2005;165:916-22. 
[31] Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood 
pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 
24,000 participants. Circulation. 2005;112:2301-6. 
[32] Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med. 
2008;86:615-21.
[33] Buckley JP. The central effects of the renin-angiotensin system. Clin Exp 
Hypertens A. 1988;10:1-16. 
[34] van Houten M, Schiffrin EL, Mann JF, Posner BI, Boucher R. 
Radioautographic localization of specific binding sites for blood-borne angiotensin II 
in the rat brain. Brain Res. 1980;186:480-5. 
[35] Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev 
Physiol. 1987;49:413-35. 
[36] Saavedra JM. Brain angiotensin II: new developments, unanswered questions 
and therapeutic opportunities. Cell Mol Neurobiol. 2005;25:485-512. 
[37] Saavedra JM, Benicky J, Zhou J. Mechanisms of the Anti-Ischemic Effect of 
Angiotensin II AT( 1 ) Receptor Antagonists in the Brain. Cell Mol Neurobiol. 
2006;26:1099-111.
41
[38] Spillantini MG, Panconesi A, Del Bianco PL, Sicuteri F. Enkephalinase and 
angiotensin converting enzyme activities in human venous and arterial plasma. 
Neuropeptides. 1986;8:111-7. 
[39] Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central 
dysnociception (migraine and related headache). Cephalalgia. 1981;1:229-32. 
[40] Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache. 
1995;35:470-1.
[41] Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of 
migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, 
placebo controlled, crossover study. BMJ. 2001;322:19-22. 
[42] Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in 
patients with hypertension/prehypertension. Headache. 2006;46:503-7. 
[43] Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II 
receptor antagonists in preventing headache: a systematic overview and meta-
analysis. Am J Med. 2002;112:642-6. 
[44] Onder G, Pahor M, Gambassi G, Federici A, Savo A, Carbonin P, Bernabei R. 
Association between ACE inhibitors use and headache caused by nitrates among 
hypertensive patients: results from the Italian group of pharmacoepidemiology in the 
elderly (GIFA). Cephalalgia. 2003;23:901-6. 
[45] Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Reduction 
in the therapeutic intensity of abortive migraine drug use during ACE inhibition 
therapy--a pilot study. Pharmacoepidemiol Drug Saf. 2004;13:41-7. 
[46] Russell MB. Is migraine a genetic illness? The various forms of migraine 
share a common genetic cause. Neurol Sci. 2008;29 Suppl 1:S52-4. 
[47] Paterna S, Di Pasquale P, D'Angelo A, Seidita G, Tuttolomondo A, Cardinale 
A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an 
increase in frequency of migraine attacks in patients suffering from migraine without 
aura. Eur Neurol. 2000;43:133-6. 
[48] Kowa H, Fusayasu E, Ijiri T, Ishizaki K, Yasui K, Nakaso K, et al. 
Association of the insertion/deletion polymorphism of the angiotensin I-converting 
enzyme gene in patients of migraine with aura. Neurosci Lett. 2005;374:129-31. 
[49] Lea RA, Ovcaric M, Sundholm J, Solyom L, Macmillan J, Griffiths LR. 
Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate 
reductase may act in combination to increase migraine susceptibility. Brain Res Mol 
Brain Res. 2005;136:112-7. 
[50] Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The 
homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a 
genetic risk factor for migraine. Am J Med Genet. 2000;96:762-4. 
[51] Lin JJ, Wang PJ, Chen CH, Yueh KC, Lin SZ, Harn HJ. Homozygous deletion 
genotype of angiotensin converting enzyme confers protection against migraine in 
man. Acta Neurol Taiwan. 2005;14:120-5. 
[52] Kara I, Ozkok E, Aydin M, Orhan N, Cetinkaya Y, Gencer M, et al. Combined 
effects of ACE and MMP-3 polymorphisms on migraine development. Cephalalgia. 
2007;27:235-43.
[53] Kaneko S, Mori A, Tamura S, Satoh M, Takagi H. Intracerebroventricular 
administration of angiotensin II attenuates morphine-induced analgesia in mice. 
Neuropharmacology. 1985;24:1131-4. 
[54] Haulica I, Neamtu C, Stratone A, Petrescu G, Branisteanu D, Rosca V, 
Slatineanu S. Evidence for the involvement of cerebral renin-angiotensin system 
(RAS) in stress analgesia. Pain. 1986;27:237-45. 
42
[55] Irvine RJ, White JM, Head RJ. The renin angiotensin system and nociception 
in spontaneously hypertensive rats. Life Sci. 1995;56:1073-8. 
[56] Norman JA, Autry WL, Barbaz BS. Angiotensin-converting enzyme inhibitors 
potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its 
degradation in mouse brain. Mol Pharmacol. 1985;28:521-6. 
[57] Pelegrini-da-Silva A, Martins AR, Prado WA. A new role for the renin-
angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-
mediated modulation of nociception. Neuroscience. 2005;132:453-63. 
[58] Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects 
of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist 
in mice. Life Sci. 1996;59:PL331-6. 
[59] Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased 
plasma substance P and CGRP levels, and high ACE activity in migraineurs during 
headache-free periods. Pain. 2007;128:209-14. 
[60] Ba'albaki H RA. Mast cells activate the renin angiotensin system and 
contribute to migraine: A hypothesis. Headache. 2007. 
[61] Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The 
role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49:65-
76.
[62] Carvalho RF, Ribeiro RA, Falcao RA, Lima RC, Leitao RF, Alcantara C, et al. 
Angiotensin II potentiates inflammatory edema in rats: Role of mast cell 
degranulation. Eur J Pharmacol. 2006;540:175-82. 
[63] Mackins CJ, Kano S, Seyedi N, Schafer U, Reid AC, Machida T, et al. 
Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine 
release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-70. 
[64] Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, Letourneau R, et al. 
Stress-induced intracranial mast cell degranulation: a corticotropin-releasing
hormone-mediated effect. Endocrinology. 1995;136:5745-50. 
[65] Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a 
molecular target for migraine therapy. Ann Neurol. 2002;51:507-16. 
[66] Sarchielli P, Floridi A, Mancini ML, Rossi C, Coppola F, Baldi A, et al. NF-
kappaB activity and iNOS expression in monocytes from internal jugular blood of 
migraine without aura patients during attacks. Cephalalgia. 2006;26:1071-9. 
[67] Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II 
activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney 
Int. 2002;61:1986-95. 
[68] Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega 
M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear 
factor-kappa B activation, monocyte chemoattractant protein-1 expression, and 
macrophage infiltration in a rabbit model of early accelerated atherosclerosis. 
Circulation. 1997;95:1532-41. 
[69] Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension 
caused by angiotensin II infusion involves increased superoxide production in the 
central nervous system. Circ Res. 2004;95:210-6. 
[70] Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Marini C, Carolei A. 
Flunarizine effects on oxidative stress in migraine patients. Cephalalgia. 2004;24:528-
32.
[71] Dreier JP, Kleeberg J, Petzold G, Priller J, Windmuller O, Orzechowski HD, 
et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the 
rat: a model for an endothelial trigger of migrainous aura? Brain. 2002;125:102-12. 
43
[72] Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, 
Tfelt-Hansen P. Involvement of calcitonin gene-related peptide in migraine: regional 
cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 
2008;9:151-7.
[73] Portaluppi F, Vergnani L, Margutti A, Ambrosio MR, Bondanelli M, 
Trasforini G, et al. Modulatory effect of the renin-angiotensin system on the plasma 
levels of calcitonin gene-related peptide in normal man. J Clin Endocrinol Metab. 
1993;77:816-20.
[74] Schelman WR, Kurth JL, Berdeaux RL, Norby SW, Weyhenmeyer JA. 
Angiotensin II type-2 (AT2) receptor-mediated inhibition of NMDA receptor 
signalling in neuronal cells. Brain Res Mol Brain Res. 1997;48:197-205. 
[75] Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: 
therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995;15:181-9. 
[76] Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G. Head-HUNT: validity 
and reliability of a headache questionnaire in a large population-based study in 
Norway. Cephalalgia. 2000;20:244-51. 
[77] Sevre K, Rostrup M. [Measurements of heart rate variability and baroreflex 
sensitivity]. Tidsskr Nor Laegeforen. 2001;121:3059-64. 
[78] La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: measurement and 
clinical implications. Ann Noninvasive Electrocardiol. 2008;13:191-207. 
[79] Stovner L, Andrée C, On behalf of the Eurolight Steering C. Impact of 
headache in Europe: a review for the Eurolight project. The Journal of Headache and 
Pain. 2008;9:139-46. 
[80] Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of 
recurrent migraine: a meta-analytic review. Headache. 1991;31:333-40. 
[81] Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, De 
Beukelaar F. Efficacy and tolerability in migraine prophylaxis of flunarizine in 
reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 
2002;22:209-21.
[82] Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of 
migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81-4. 
[83] Mathew NT. Antiepileptic drugs in migraine prevention. Headache. 2001;41 
Suppl 1:S18-24. 
[84] Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a 
Cochrane review. Cephalalgia. 2008;28:585-97. 
[85] Stoukides CA, McVoy HJ, Kaul AF. Candesartan cilexetil: an angiotensin II 
receptor blocker. Ann Pharmacother. 1999;33:1287-98. 
[86] Chung OY, Bruehl S. The impact of blood pressure and baroreflex sensitivity 
on wind-up. Anesth Analg. 2008;107:1018-25. 
[87] Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady 
component of blood pressure: a cross-sectional analysis and a prospective analysis on 
cardiovascular mortality. Hypertension. 1989;13:392-400. 
[88] Thrasher TN. Baroreceptors, baroreceptor unloading, and the long-term 
control of blood pressure. Am J Physiol Regul Integr Comp Physiol. 2005;288:R819-
27.
[89] Bernstein IM, Thibault A, Mongeon JA, Badger GJ. The influence of 
pregnancy on arterial compliance. Obstet Gynecol. 2005;105:621-5. 
[90] Visontai Z, Lenard Z, Studinger P, Rigo J, Jr., Kollai M. Impaired baroreflex 
function during pregnancy is associated with stiffening of the carotid artery. 
Ultrasound Obstet Gynecol. 2002;20:364-9. 
44
[91] Hesse C, Charkoudian N, Liu Z, Joyner MJ, Eisenach JH. Baroreflex 
sensitivity inversely correlates with ambulatory blood pressure in healthy 
normotensive humans. Hypertension. 2007;50:41-6. 
[92] Virtanen R, Jula A, Huikuri H, Kuusela T, Helenius H, Ylitalo A, et al. 
Increased pulse pressure is associated with reduced baroreflex sensitivity. J Hum 
Hypertens. 2004;18:247-52. 
[93] Bruehl S, Carlson CR, McCubbin JA. The relationship between pain 
sensitivity and blood pressure in normotensives. Pain. 1992;48:463-7. 
[94] Chung OY, Bruehl S, Diedrich L, Diedrich A, Chont M, Robertson D. 
Baroreflex sensitivity associated hypoalgesia in healthy states is altered by chronic 
pain. Pain. 2007. 
[95] Haberthur C, Schachinger H, Langewitz W, Ritz R. Effect of beta blockade 
with and without sympathomimetic activity (ISA) on sympathovagal balance and 
baroreflex sensitivity. Clin Physiol. 1999;19:143-52. 
[96] De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, et al. 
Comparison of the effect of valsartan and lisinopril on autonomic nervous system 
activity in chronic heart failure. Am Heart J. 2003;146:E17. 
[97] Heusser K, Vitkovsky J, Schmieder RE, Schobel HP. AT1 antagonism by 
eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 
2003;107:45-51.
[98] Havanka-Kanniainen H. Cardiovascular reflex responses during migraine 
attack. Headache. 1986;26:442-6. 
[99] Boiardi A, Munari L, Milanesi I, Paggetta C, Lamperti E, Bussone G. 
Impaired cardiovascular reflexes in cluster headache and migraine patients: evidence 
for an autonomic dysfunction. Headache. 1988;28:417-22. 
[100] Cortelli P, Pierangeli G, Parchi P, Contin M, Baruzzi A, Lugaresi E. 
Autonomic nervous system function in migraine without aura. Headache. 
1991;31:457-62.
[101] Appel S, Kuritzky A, Zahavi I, Zigelman M, Akselrod S. Evidence for 
instability of the autonomic nervous system in patients with migraine headache. 
Headache. 1992;32:10-7. 
45

Paper I
 
Is not included due to copyright 
Paper II

BioMed Central
Page 1 of 5
(page number not for citation purposes)
BMC Neurology
Open AccessResearch article
Angiotensin-converting enzyme gene insertion/deletion 
polymorphism in migraine patients
Erling Tronvik*1,2, Lars J Stovner1,2, Gunnar Bovim2, Linda R White1,2,
Amanda J Gladwin3, Kathryn Owen3 and Harald Schrader1,2
Address: 1Department of Neurosciences, Norwegian University of Science and Technology, Trondheim, Norway, 2Department of Neurology and 
Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway and 3AstraZeneca, R&D Genetics, Mereside, Alderley Park, 
Macclesfield, Cheshire, SK10 4TG, UK
Email: Erling Tronvik* - Erling.Tronvik@ntnu.no; Lars J Stovner - Lars.Stovner@ntnu.no; Gunnar Bovim - Gunnar.Bovim@ntnu.no; 
Linda R White - Linda.White@ntnu.no; Amanda J Gladwin - Amanda.Gladwin@astrazeneca.com;
Kathryn Owen - Kathryn.Owen@astrazeneca.com; Harald Schrader - Harald.Schrader@ntnu.no
* Corresponding author    
Abstract
Background: The main objective of this study was to investigate the angiotensin converting
enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura)
compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor,
lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to
ACE genotype.
Methods: 347 migraine patients aged 18–68 (155 migraine without aura (MoA), 187 migraine with
aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years
of age were included in the study. A polymerase chain reaction (PCR) was performed on the
genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms.
Results: No significant differences between migraine patients and controls were found with regard
to ACE genotype and allele distributions. Furthermore, there was no significant difference between
the controls and the MwA or MoA subgroups.
Conclusion: In our sample there is no association between ACE genotype or allele frequency and
migraine. In addition, ACE genotype in our experience did not predict the clinical response to
lisinopril or candesartan used as migraine prophylactics.
Background
Two small open studies reported an improvement of the
headache in migraine patients using an angiotensin-con-
verting enzyme (ACE) inhibitor [1,2]. Indirectly, a benefi-
cial effect of angiotensin II receptor blockers (ARB's) on
headache is shown in a meta-analysis on side effects
reported in placebo controlled trials including over 12
000 patients [3]. Two randomized, placebo controlled
studies conducted by our research group have evidence for
efficacy of an ACE inhibitor (lisinopril) and an ARB (can-
desartan) in migraine prophylaxis [4,5]. This and other
evidence points in the direction of involvement of the
renin-angiotensin system (RAS) in migraine pathophysi-
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ology. (For further discussion on possible mechanisms
see reference [6]).
The human angiotensin converting enzyme (ACE) gene
consists of either an insertion (I) allele or a deletion (D)
allele forming three possible genotypes: II, ID or DD.
Many studies have suggested an association between the
ACE-D allele and cardiovascular diseases [7]. For migraine
an Italian (Paterna) [8], an Australian (Lea) [9], and a Jap-
anese (Kowa) [10] study has demonstrated different
results regarding whether an association between the ACE
polymorphisms and this condition exists (Table 1).
The objectives of the present study were two-fold. Firstly
we wanted to examine whether a beneficial effect in the
above mentioned migraine prophylactic studies [4,5]
could be predicted by ACE genotype, a question that has
also been raised in a recent publication [11]. Secondly we
wanted to investigate the ACE genotype as a possible risk
factor for migraine with (MwA) and without (MoA) aura
in a Norwegian population.
Methods
Included in the study were 347 migraine patients aged
18–68 (155 MwA, 187 MoA and 5 missing aura subgroup
data, based on ICHD-2 criteria [12]) and 403 healthy
non-migrainous controls > 40 years of age. The
migraineurs were recruited partly from the lisinopril [4]
(n = 49) and candesartan [5] (n = 59) studies, and the
remaining group (n = 239) from the outpatient clinic of
the Department of Neurology, Trondheim University
Hospital. The patients and the controls were recruited
from the same area and only subjects with Nordic ethnic
background were included. The diagnosis was confirmed
by an experienced clinical neurologist. Responder status
in the candesartan and lisinopril studies was defined as a
reduction in days with headache of at least 50% in the
treatment period compared to the placebo period. Non-
responders were the subjects not defined as responders
and with both genotype and response data available. No
patients were included in both the lisinopril and cande-
sartan studies. The control group was recruited in collab-
oration with the Department of Immunology and
Transfusion Medicine and criteria for inclusion were no
present or former history of migraine or other types of
chronic headaches, no history of epilepsy or of hyperten-
sion in need of medical treatment, and age > 40 years
(since status as "non-migraineur" cannot be determined
with relative certainty before this age). No direct interview
was made in the control group, but the participants filled
out a questionnaire to determine eligibility for participa-
tion. In addition to not having migraine the control group
was required to have no other headache condition and
less than one headache day per month.
The migraine group had a mean age of 41 years (standard
deviation (SD): ± 12 years) and consisted of 268 women
and 79 men. Median age of migraine onset was 16 years
Table 1: ACE genotype and allele distributions among controls and migraine patients in different studies
Genotypes Alleles
N DD(%) ID(%) II(%) D(%) I(%)
Controls
Tronvik 403 92 (26.6) 204 (50.6) 107 (22.8) 388 (48.1) 418 (51.9)
Paterna (ref 8) 201 75 (37.3) 101 (50.3) 25 (12.4) 251 (62.4) 151 (37.6)
Lea (ref 9) 244 76 (31.1) 122 (50.0) 46 (18.9) 274 (56.1) 214 (43.9)
Kowa (ref 10) 248 31 (12.5) 114 (46.0) 103 (41.5) 176 (35.5) 320 (64.5)
Migraine
Tronvik 347 78 (22.5) 186 (53.6) 83 (23.9) 342 (49.3) 352 (50.7)
Paterna 302 146 (48.3) 129 (42.7) 27 (9.0) 421 (69.7) 183 (30.3)
Lea 250 77 (30.8) 142 (56.8) 31 (12.4) 296 (59.2) 204 (40.8)
Kowa 176 33 (18.7) 86 (48.9) 57 (32.4) 152 (43.2) 200 (56.8)
MwA subgroup
Tronvik 155 34 (21.9) 87 (56.1) 34 (21.9) 155 (50.0) 155 (50.0)
Paterna NA NA NA NA NA NA
Lea 151 48 (31.8) 85 (56.3) 18 (11.9) 181 (59.9) 121 (40.1)
Kowa 54 14 (25.9)* 26 (48.2) 14 (25.9) 54 (50.0)* 54 (50.0)
MoA subgroup
Tronvik 187 43 (23.0) 96 (51.3) 48 (25.7) 182 (48.7) 192 (51.3)
Paterna 302 146 (48.3)* 129 (42.7) 27 (9.0) 421 (69.7) 183 (30.3)
Lea 99 29 (29.3) 57 (57.6) 13 (13.1) 115 (58.1) 83 (41.9)
Kowa 122 19 (15.6) 60 (49.2) 43 (35.2) 98 (35.2) 146 (59.8)
* Reported significant finding for genotype or allele frequencies
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and median attack frequency was 4.0 attacks per month.
In the control group with 233 women and 170 men, mean
age was 50 years (SD: ± 7 years).
311 of the samples were genotyped by AstraZeneca, R&D
Genetics, UK, and 439 samples were genotyped at the
Department of Neurology, Trondheim University Hospi-
tal, Norway.
Genomic DNA preparation and polymerase chain reaction 
(PCR) analysis
DNA was extracted from peripheral EDTA-blood stored at
-80°C. The D and I alleles were identified on the basis of
PCR amplification of the respective fragments from intron
16 of the ACE gene. The oligonucleotide primers [13,14]
used (MedProbe) were sense (forward): 5' CTGGAGAC-
CACTCCCATCCTTTCT 3' and antisense (reverse): 5' GAT-
GTGGCCATCACATTCGTCAGAT 3'. Amplification was
performed with 0.5 Pmol of each primer. The PCR prod-
uct was a 191 bp fragment in the absence, and a 479 bp
fragment in the presence of the insertion. Homozygous D
alleles were confirmed using the insertion-specific primer
5' TTTGAGACGGAGTCTCGCTC 3'.
Part of the samples (n = 311) were amplified using a ther-
mal cycler and the products separated on 2% agarose gel.
The remaining samples (n = 439) were analyzed using a
LightCycler instrument (Roche). Amplification condi-
tions for the first method were 1.2 mM MgCl2, 1 U Ampl-
iTaq Gold, 200 PM dNTPs and 5 PL DNA template in a
total reaction volume of 25 PL, enzyme activation at 94°C
for 20 min, denaturation at 94°C for 1 min, annealing at
58°C for 1 min and extension at 72°C for 2 min for a total
of 32 cycles. Samples analyzed by LightCycler used the
FastStart DNA Master SYBR Green 1 mix, which includes
Taq DNA polymerase (Roche Diagnostics), plus 3 mM
MgCl2, and 2 PL DNA template, in a total reaction volume
of 20 PL with enzyme activation at 95°C for 10 min,
denaturation at 95°C for 10 s, annealing at 50°C for 5 s,
and elongation at 72°C for 15 s, for a total of 35 cycles.
The fluorescence intensity of the double-strand specific
SYBR Green I is directly proportional to the amount of
PCR product formed. Melting curves indicated the respec-
tive melting temperatures of the 191 bp and 479 bp frag-
ments to be 84.5°C and 91.8°C respectively, with
samples from heterozygotes displaying a peak at both
temperatures. Reaction products were confirmed on 2%
agarose gel. The ratio between cases and controls was the
same for both methods of analysis and blinded control
experiments in 10 random patients analysed by the first
method were confirmed by the second method.
Statistical analysis
Observed genotype count was used to calculate genotype
and allele frequencies for the ACE I/D polymorphism. The
expected genotype proportions were calculated and com-
pared to the observed proportions according to the
Hardy-Weinberg law. The significance level was set at p <
0.05. For comparison between groups we used the F2 test
with one or two degrees of freedom. To compare means
(age of debut, frequency of migraine/headache) we used
one-way ANOVA. Statistical analysis were performed
using SPSS version 13.0 for Windows (SPSS Inc., Chicago,
IL, USA). Power calculation for the association between
ACE polymorphisms and migraine was performed with
the method described by Altman with correction for une-
qual sample sizes [15]. For the association between ACE
polymorphisms and drug response, we performed a one
sample two tailed test with alpha = 0.05.
Ethics
The study was approved by the regional committee for
ethics in medical research, and by the Norwegian data
inspectorate. All subjects included gave a written
informed consent.
Results
The observed genotypes in the control population did not
deviate significantly from the Hardy-Weinberg equilib-
rium (p = 0.98). With regard to the genotype and allele
distributions, no significant differences between migraine
patients and controls were detected, even though the ACE-
D allele tended to be more frequent (p = 0.058) among
responders than non-responders in the candesartan group
(Table 2). Furthermore, there was no significant difference
between the controls and the MwA or MoA subgroups,
nor between responders and non-responders to lisinopril
and candesartan, and no difference was detected when
stratifying by sex. Within the migraine group differences
in genotype could not explain the presence of aura (n =
342, missing data = 5, p = 0.64), of coexisting tension-type
headache among migraineurs (n = 343, missing data = 4,
p = 1.0), differences in age of debut (n = 342, missing = 5,
p = 0.69) or frequency of migraine (n = 342, missing = 5,
p = 0.52) or in headache frequency as recorded in the pla-
cebo period in the candesartan study (n = 56, missing = 3,
p = 0.77).
Frequencies of the genotypes and alleles for the different
studies are presented in Table 1. There are large differences
in genotypes and alleles among the controls. E.g. the II
genotype varies between 12.4 and 41.5 and the D-allele
between 35.5 and 62.4%.
Discussion
In the present Norwegian sample, there is no difference in
ACE genotype or allele frequency in a migraine group
compared to a control group. Associations between ACE
polymorphism and migraine reported in other studies are
not consistent and have been detected in different diag-
BMC Neurology 2008, 8:4 http://www.biomedcentral.com/1471-2377/8/4
Page 4 of 5
(page number not for citation purposes)
nostic or sex categories. The results of these studies are
shown in Table 1. In addition a recently published study
from Taiwan found no differences in ACE allelic frequen-
cies between migraine patients and controls, but stratified
by gender the DD frequency was significantly lower in
male migraineurs than controls (not included in Table 1
because only the abstract was published in the English
language) [16]. Findings that the DD genotype is more
frequent in MoA [8] and MwA [10] or less frequent in
male migraineurs [16] are not supported by our data. Our
population which is the largest to date used to study the
relationship between ACE polymorphism and migraine
(MoA and MwA) should have >80% power to detect an
association of the same magnitude as in the study by
Paterna et al [8]. Our study also did not find a relationship
between ACE genotype and response to prophylactic
drugs influencing the RAS. The allele frequency in the
responders versus non-responders in the candesartan
group had a p-value of 0.058 and with low numbered
groups the risk of a false negative result is present.
The purpose of looking at the association between
responders in the two clinical trials and ACE genotype was
not to detect a small theoretical association, in which case
this subgroup analyses would be underpowered, but to
see whether there was an association so strong that it
would be valuable in clinical use predicting response in
migraine – prophylactic treatment. That is whether it
would be clinically beneficial to use ACE genotype to pre-
dict whether the patient would respond to the drug or not.
Our opinion is that in order for an association to be clin-
ical valuable at least 75–100% of responders to a
migraine-prophylactic drug should have a specific ACE-
genotype. The power of our study to measure a percentage
of 75% DD among the candesartan responders with the
control population as reference is > 80%.
A limitation of the study is that the control group was not
directly interviewed increasing the risk of migraineurs self-
reporting themselves as non-migraineurs and thereby
increasing the risk of type II errors. In order to minimize
this problem participants in the control group were
required to have no other headache condition and less
than one headache day per month.
Population stratification refers to differences in allele fre-
quencies between cases and controls due to systematical
differences in ancestry rather than in the association of
genes with disease [17,18]. There are large differences in
the frequencies of the ACE-alleles in different populations
(Table 1). Hence, due to the problem with population
stratification we did not find it meaningful to perform a
statistical analysis of the merged data of all these studies.
This might have been misleading also because the way
diagnosis were made, both of migraineurs and controls,
may differ somewhat between the studies.
Conclusion
There was no difference in ACE genotype distribution
between a migraine and a control population in our mate-
rial. Our study also indicates that ACE genotyping will not
be a valuable tool for predicting clinical response of drugs
influencing the angiotensin system in headache treat-
ment. It is, however, important that these findings should
be confirmed in other studies with more patients and
among different ethnic groups.
Abbreviations
RAS, renin-angiotensin system; ACE, angiotensin convert-
ing enzyme; MoA, migraine without aura; MwA, migraine
with aura; ARB's, angiotensin II receptor blockers.
Table 2: ACE genotype and allele distributions among controls and migraine patients in a Norwegian population
Genotypes Alleles
N DD(%) ID(%) II(%) D(%) I(%)
Controls 403 92 (26.6) 204 (50.6) 107 (22.8) 388 (48.1) 418 (51.9)
Migraine 347 78 (22.5) 186 (53.6) 83 (23.9) 342 (49.3) 352 (50.7)
MwA subgroup 155 34 (21.9) 87 (56.1) 34 (21.9) 155 (50.0) 155 (50.0)
MoA subgroup 187 43 (23.0) 96 (51.3) 48 (25.7) 182 (48.7) 192 (51.3)
Lisinopril responders 12 2 (16.7) 6 (50.0) 4 (33.3) 10 (41.7) 14 (58.3)
Lisinopril non-responders 37 10 (27.0) 16 (43.2) 11 (29.7) 36 (48.6) 38 (51.4)
Candesartan responders* 18 7 (38.9) 9 (50.0) 2 (11.1) 23 (63.9) 13 (36.1)
Candesartan non-responders* 38 8 (21.1) 18 (47.4) 12 (31.6) 34 (44.7) 42 (55.3)
Responders combined 30 9 (30.0) 15 (50.0) 6 (20.0) 33 (55.0) 27 (45.0)
Non-responders combined 75 18 (24.0) 34 (45.3) 23 (30.7) 70 (46.7) 80 (53.3)
* Response data available in 56 of 59 genotyped
Allele and genotype frequency distributions are not significantly different for any diagnostic groups (migraine, MwA, MoA) vs controls, or for 
responders vs non-responders (p > 0.05).
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